CIK 0001654151
DCPH Deciphera Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jun 11, 2024.
In brief
Deciphera Pharmaceuticals, Inc. (DCPH) has 41 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 11, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
19 open-market trades have been scored at DCPH. The newest: Jama Pitman (SVP, Chief Development Officer) sold $35k of stock on Feb 16, 2024, filed Feb 20, 2024, scored 36 (weak). The largest of the 19 shown: Steven L. Hoerter (President and CEO) sold $471k on Dec 13, 2023, scored 67 (notable). 4 insiders sold within 14 days of each other around Feb 16, 2024.
1 Form 144 notice of planned sales is on file, the latest filed Nov 30, 2023.
Last 90 days
Signals
Open-market buys and sells at Deciphera Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Jama Pitman SVP, Chief Development Officer sell | $35k 2,267 shares | -3% | - | |
| 36Weak | Matthew L Sherman EVP & Chief Medical Officer sell | $41k 2,615 shares | -2% | - | |
| 36Weak | Daniel C. Martin Chief Commercial Officer sell | $35k 2,267 shares | -4% | - | |
| 43Moderate | Thomas Patrick Kelly Chief Financial Officer sell | $47k 3,010 shares | -4% | - | |
| 30Weak | Daniel C. Martin Chief Commercial Officer sell | $23k 1,624 shares | -3% | - | |
| 43Moderate | Thomas Patrick Kelly Chief Financial Officer sell | $35k 2,435 shares | -4% | - | |
| 30Weak | Jama Pitman SVP, Chief Development Officer sell | $23k 1,624 shares | -3% | - | |
| 36Weak | Matthew L Sherman EVP & Chief Medical Officer sell | $35k 2,435 shares | -3% | - | |
| 36Weak | Matthew L Sherman EVP & Chief Medical Officer sell | $43k 2,792 shares | -3% | - | |
| 35Weak | Daniel C. Martin Chief Commercial Officer sell | $27k 1,727 shares | -3% | - | |
| 43Moderate | Thomas Patrick Kelly Chief Financial Officer sell | $43k 2,792 shares | -4% | - | |
| 35Weak | Jama Pitman See Remarks sell | $26k 1,662 shares | -3% | - | |
| 67Notable | Steven L. Hoerter President and CEO sell | $471k 30,664 shares | -30% | - | |
| 52Moderate | Daniel C. Martin Chief Commercial Officer sell | $224k 17,801 shares | -28% | - | |
| 63Notable | Steven L. Hoerter President and CEO sell | $259k 21,573 shares | -35% | - | |
| 42Moderate | Thomas Patrick Kelly Chief Financial Officer sell | $28k 2,316 shares | -4% | - | |
| 30Weak | Daniel C. Martin Chief Commercial Officer sell | $17k 1,407 shares | -2% | - | |
| 30Weak | Jama Pitman See Remarks sell | $17k 1,407 shares | -3% | - | |
| 35Weak | Matthew L Sherman EVP & Chief Medical Officer sell | $28k 2,360 shares | -3% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 30, 2023 | Martin Daniel C. Officer | 17,801 0.02% of outstanding | $224k | Nov 30, 2023 | $17k |
Transactions
The newest 50 of 141 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Jama Pitman SVP, Chief Development Officer | AGrant or award Common Stock | +20,163 | - | - | 88,194 | Jun 11, 2024 |
| Jun 11, 2024 | Edward J. Benz JR director | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,233 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | John Richard Martin director | DDisposition to issuer Stock Option (Right to Buy)derivative | -52,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dennis Leo Walsh director | UTender of shares Common Stock | -11,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dashyant Dhanak EVP & Chief Scientific Officer | AGrant or award Common Stock | +25,913 | - | - | 184,088 | Jun 11, 2024 |
| Jun 11, 2024 | Matthew L Sherman EVP & Chief Medical Officer | AGrant or award Common Stock | +34,157 | - | - | 144,290 | Jun 11, 2024 |
| Jun 11, 2024 | Ron Squarer director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Patricia L Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,233 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Daniel C. Martin Chief Commercial Officer | AGrant or award Common Stock | +20,163 | - | - | 75,281 | Jun 11, 2024 |
| Jun 11, 2024 | Susan L. Kelley director | DDisposition to issuer Stock Option (Right to Buy)derivative | -24,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Thomas Patrick Kelly Chief Financial Officer | AGrant or award Common Stock | +34,157 | - | - | 114,507 | Jun 11, 2024 |
| Jun 11, 2024 | James Arthur Bristol director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Bristol Survivor's Trust | -22,150 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Steven L. Hoerter President and CEO | AGrant or award Common Stock | +286,075 | - | - | 358,838 | Jun 11, 2024 |
| Jun 11, 2024 | Franklin Stuart Friedman director | UTender of shares Common Stock | -10,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Thomas Patrick Kelly Chief Financial Officer | DDisposition to issuer Common Stock | -72,029 | - | - | 42,478 | Jun 11, 2024 |
| Jun 11, 2024 | Jama Pitman SVP, Chief Development Officer | DDisposition to issuer Common Stock | -53,951 | - | - | 34,243 | Jun 11, 2024 |
| Jun 11, 2024 | Dennis Leo Walsh director | DDisposition to issuer Stock Option (Right to Buy)derivative | -52,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Franklin Stuart Friedman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Edward J. Benz JR director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,181 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Matthew L Sherman EVP & Chief Medical Officer | DDisposition to issuer Common Stock | -72,029 | - | - | 72,261 | Jun 11, 2024 |
| Jun 11, 2024 | Steven L. Hoerter President and CEO | DDisposition to issuer Common Stock | -286,075 | - | - | 72,763 | Jun 11, 2024 |
| Jun 11, 2024 | Susan L. Kelley director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Patricia L Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,181 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | John Richard Martin director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Daniel C. Martin Chief Commercial Officer | DDisposition to issuer Common Stock | -43,951 | - | - | 31,330 | Jun 11, 2024 |
| Jun 11, 2024 | Dashyant Dhanak EVP & Chief Scientific Officer | DDisposition to issuer Common Stock | -184,088 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Ron Squarer director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | James Arthur Bristol director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Bristol Survivor's Trust | -67,494 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | James Arthur Bristol director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Bristol Survivor's Trust | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dennis Leo Walsh director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Susan L. Kelley director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Jama Pitman SVP, Chief Development Officer | UTender of shares Common Stock | -34,243 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dashyant Dhanak EVP & Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,900 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | John Richard Martin director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Daniel C. Martin Chief Commercial Officer | UTender of shares Common Stock | -31,330 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Franklin Stuart Friedman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Steven L. Hoerter President and CEO | UTender of shares Common Stock | -72,763 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Edward J. Benz JR director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Matthew L Sherman EVP & Chief Medical Officer | UTender of shares Common Stock | -72,261 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Thomas Patrick Kelly Chief Financial Officer | UTender of shares Common Stock | -42,478 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Patricia L Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Ron Squarer director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,269 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Patricia L Allen director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | James Arthur Bristol director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Bristol Survivor's Trust | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dennis Leo Walsh director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,570 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Susan L. Kelley director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,269 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | John Richard Martin director | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Daniel C. Martin Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -62,971 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Dashyant Dhanak EVP & Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -69,100 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | Steven L. Hoerter President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -395,735 | - | - | 0 | Jun 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Patricia L Allendirector
- Edward J. Benz JRdirector
- James Arthur Bristoldirector
- Dashyant DhanakEVP & Chief Scientific Officer
- Franklin Stuart Friedmandirector
- Steven L. HoerterPresident and CEO
- Susan L. Kelleydirector
- Thomas Patrick KellyChief Financial Officer
- Daniel C. MartinChief Commercial Officer
- John Richard Martindirector
- Jama PitmanSVP, Chief Development Officer
- Matthew L ShermanEVP & Chief Medical Officer
- Ron Squarerdirector
- Dennis Leo Walshdirector
Questions about DCPH
Answered from the filings on this page, as of the latest one.
Are insiders buying DCPH?
No. In the last 90 days no insider at Deciphera Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade DCPH on the open market?
Jama Pitman (SVP, Chief Development Officer) sold $35k of DCPH on Feb 16, 2024 and filed the Form 4 on Feb 20, 2024. InsiderTell scored 36 (weak), with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Deciphera Pharmaceuticals, Inc.?
14 people have filed a Form 4 at Deciphera Pharmaceuticals, Inc., among them Patricia L Allen (director), Edward J. Benz JR (director), James Arthur Bristol (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.